Helen Diller Family Comprehensive Cancer Center - Imaging Post — San Francisco, California

Helen Diller Family Comprehensive Cancer Center - Imaging Post is a clinical research site located in San Francisco, California, United States 94115.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Helen Diller Family Comprehensive Cancer Center - Imaging Post has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Urothelial Carcinoma.

Sponsors: Seagen, a wholly owned subsidiary of Pfizer.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in San Francisco

Browse all research sites in California · View every site in San Francisco

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Helen Diller Family Comprehensive Cancer Center - Imaging Post?

Helen Diller Family Comprehensive Cancer Center - Imaging Post has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Helen Diller Family Comprehensive Cancer Center - Imaging Post conducted?

Helen Diller Family Comprehensive Cancer Center - Imaging Post has 1 clinical trials on record, with 1 currently active. Their work covers Urothelial Carcinoma.

Is Helen Diller Family Comprehensive Cancer Center - Imaging Post accredited by Crixeo Clinical Trials?

Helen Diller Family Comprehensive Cancer Center - Imaging Post has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Helen Diller Family Comprehensive Cancer Center - Imaging Post?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.